| scholarly article | Q13442814 |
| P356 | DOI | 10.1046/J.1440-1711.2004.01238.X |
| P698 | PubMed publication ID | 15186254 |
| P50 | author | Mark J. Smyth | Q38544864 |
| Dale I Godfrey | Q56957983 | ||
| Daniel G Pellicci | Q77601843 | ||
| P2093 | author name string | Stuart P Berzins | |
| Mitchell Kronenberg | |||
| Stephane Sidobre | |||
| Alan Baxter | |||
| Kon Kyparissoudis | |||
| Kristen J Hammond | |||
| P433 | issue | 3 | |
| P304 | page(s) | 247-252 | |
| P577 | publication date | 2004-06-01 | |
| P1433 | published in | Immunology & Cell Biology | Q13731918 |
| P1476 | title | Systemic NKT cell deficiency in NOD mice is not detected in peripheral blood: implications for human studies | |
| P478 | volume | 82 |
| Q35761273 | Beta-glucosylceramide: a novel method for enhancement of natural killer T lymphoycte plasticity in murine models of immune-mediated disorders |
| Q37395299 | Clinical application of NKT cell biology in type I (autoimmune) diabetes mellitus. |
| Q36858868 | Control points in NKT-cell development |
| Q39049093 | Engaging Natural Killer T Cells as 'Universal Helpers' for Vaccination |
| Q44311667 | Ex-vivo analysis of human natural killer T cells demonstrates heterogeneity between tissues and within established CD4(+) and CD4(-) subsets. |
| Q35795122 | Genetic control of murine invariant natural killer T-cell development dynamically differs dependent on the examined tissue type |
| Q47144502 | Glycolipid-peptide conjugate vaccines enhance CD8+ T cell responses against human viral proteins |
| Q35951531 | Going both ways: immune regulation via CD1d-dependent NKT cells |
| Q24701792 | Multiple immune factors are involved in controlling acute and chronic chikungunya virus infection |
| Q34288977 | NKT Cell Subsets Can Exert Opposing Effects in Autoimmunity, Tumor Surveillance and Inflammation |
| Q51828144 | Natural killer T cells: drivers or passengers in preventing human disease? |
| Q41893247 | Polymorphisms in the CD1d promoter that regulate CD1d gene expression are associated with impaired NKT cell development |
| Q34160821 | Presumed guilty: natural killer T cell defects and human disease |
| Q38028844 | Prevention and treatment of type 1 diabetes mellitus by the manipulation of invariant natural killer T cells |
| Q37688877 | Raising the NKT cell family |
| Q36124501 | Role of regulatory invariant CD1d-restricted natural killer T-cells in protection against type 1 diabetes |
| Q25255724 | Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients |
| Q36367836 | The natural killer T lymphocyte: a player in the complex regulation of autoimmune diabetes in non-obese diabetic mice |
| Q27023425 | The regulatory role of invariant NKT cells in tumor immunity |
| Q38063960 | Therapeutic manipulation of natural killer (NK) T cells in autoimmunity: are we close to reality? |
| Q35612660 | Type 1 diabetes and NKT cells: a report on the 3rd International Workshop on NKT cells and CD1-mediated antigen presentation, September 2004, Heron Island, QLD, Australia |
Search more.